NMDA Receptor Antibody (NR1)

Anti-NMDAR encephalitis emerges as a prevalent autoimmune disorder affecting the central nervous system (CNS), characterized by intricate neuropsychiatric manifestations and the detection of Immunoglobulin G (IgG) antibodies targeting the NR1 subunit of NMDA receptors. Representing a prominent variant of autoimmune limbic encephalitis, this condition typically presents with acute or subacute onset of neuropsychiatric symptoms. The key to optimal outcomes lies in the prompt identification and initiation of immunotherapy. This comprehensive review delves into the evaluation and treatment of anti-NMDAR encephalitis, underscoring the pivotal role of the healthcare team in enhancing overall care for individuals facing this condition, aligning with Hypro Diagnostics’ commitment to advancing diagnostic and therapeutic approaches.